Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Net Margin (2016 - 2025)

Historic Net Margin for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to 208.15%.

  • Voyager Therapeutics' Net Margin fell 1714300.0% to 208.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 404.05%, marking a year-over-year decrease of 4198500.0%. This contributed to the annual value of 81.25% for FY2024, which is 1341800.0% down from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' Net Margin is 208.15%, which was down 1714300.0% from 641.96% recorded in Q2 2025.
  • Voyager Therapeutics' Net Margin's 5-year high stood at 1524.26% during Q4 2022, with a 5-year trough of 3239.97% in Q1 2022.
  • In the last 5 years, Voyager Therapeutics' Net Margin had a median value of 393.32% in 2021 and averaged 600.05%.
  • As far as peak fluctuations go, Voyager Therapeutics' Net Margin plummeted by -28466500bps in 2022, and later soared by 33224000bps in 2023.
  • Over the past 5 years, Voyager Therapeutics' Net Margin (Quarter) stood at 20.34% in 2021, then soared by 7395bps to 1524.26% in 2022, then tumbled by -96bps to 62.62% in 2023, then crashed by -977bps to 549.33% in 2024, then skyrocketed by 62bps to 208.15% in 2025.
  • Its Net Margin was 208.15% in Q3 2025, compared to 641.96% in Q2 2025 and 477.25% in Q1 2025.